The 2026 PSMA & Beyond conference featured a clinical development session and presentation by Stephanie Lira discussing scaling operations in theranostics clinical research. There has been tremendous ...
Prostate-specific membrane androgen PET/CT can help clinicians intensify or de-escalate care for men with prostate cancer who ...
At the 2026 PSMA and Beyond annual meeting, Robert Reiter discusses the problems with our PSMA PET reports. Dr. Reiter ...
A PSMA PET scan found more recurrent prostate cancer at low PSA levels than a standard scan, helping guide more potentially curative treatment decisions. A newer type of prostate cancer scan called 64 ...
A new radioactive diagnostic agent for use in prostate cancer has been approved by the US Food and Drug Administration (FDA). The product, Gallium 68 PSMA-11 (Ga 68 PSMA-11), has been approved for ...
Approximately 20% to 40% of men who have surgery for localized prostate cancer will see the cancer return within 10 years, often first detected by a rising PSA blood test. When this happens, doctors ...
An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following inconclusive or reassuring results from an MRI scan, new research has found. Findings ...
Researchers in Denmark conducted a prospective single-centre study including 160 patients with newly diagnosed high-risk prostate cancer between 2021 and 2024. All the participants first underwent an ...
Study combines highly focused radiation with targeted radioactive therapy drug designed to seek out and destroy cancer cells with minimal damage to healthy tissue The Phase 2 trial, called ANDROMEDA, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results